exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087903 RNA Name: hsa-miR-206 RNA Type: miRNA Chromosome: chr6 Starnd: + Coordinate: Start Site(bp): 52144401 End Site(bp): 52144422 External Links: hsa-miR-206

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand CAPNS1 chr19 36139953 36150353 + NPEPPS chr17 47522942 47623276 + SPRED1 chr15 38252836 38357249 + SLC30A7 chr1 100896076 100981757 + DDX5 chr17 64498254 64508199 - TRIM2 chr4 153152342 153339317 + DLG3 chrX 70444835 70505490 + LASP1 chr17 38869859 38921770 + RTL8B chrX 135020513 135022542 - FOXP1 chr3 70952817 71583993 - SDCBP chr8 58552924 58582859 + NME1-NME2 chr17 51153590 51171744 + NR2C2 chr3 14947584 15053600 + TNRC6B chr22 40044817 40335808 + CREB3L2 chr7 137874979 138002086 - NETO2 chr16 47077703 47143945 - ZNF518A chr10 96129715 96205288 + PGM2 chr4 37826660 37862937 + PRR12 chr19 49591182 49626439 + PTBP1 chr19 797075 812327 + CALM1 chr14 90396502 90408268 + NME2 chr17 51165435 51171747 + AP1S1 chr7 101154456 101161596 + MAPK1 chr22 21754500 21867680 - GID4 chr17 18039408 18068405 + SMCO4 chr11 93478472 93543391 - SS18 chr18 26016253 26091217 - CWC15 chr11 94962620 94973586 - WIPF2 chr17 40219304 40284136 + WDR5 chr9 134135365 134159968 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000816 chr17 80521229 80526077 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC005332.7 chr17 68188547 68189165 + AC145207.5 chr17 81878425 81881106 - LINC00641 chr14 21200079 21206900 - MALAT1 chr11 65497688 65506516 + MIR4435-2HG chr2 111006015 111523376 - NEAT1 chr11 65422774 65445540 + RMRP chr9 35657751 35658018 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.